| Year |
Citation |
Score |
| 2020 |
Nizam A, Trump DL, Aragon-Ching JB. Characterization of Brain Metastases in Urothelial Cancers. Clinical Genitourinary Cancer. PMID 32359862 DOI: 10.1016/J.Clgc.2020.03.015 |
0.337 |
|
| 2020 |
Hourigan SK, Zhu W, S W Wong W, Clemency NC, Provenzano M, Vilboux T, Niederhuber JE, Deeken J, Chung S, McDaniel-Wiley K, Trump D. Studying the urine microbiome in superficial bladder cancer: samples obtained by midstream voiding versus cystoscopy. Bmc Urology. 20: 5. PMID 31992287 DOI: 10.1186/S12894-020-0576-Z |
0.325 |
|
| 2020 |
Onik G, Bostwick D, Vaughan DJ, Trump DL, Vega Z, Murphy T, Miessau J, Wright-Barton M, Hobbs D, Link CJ, Condra JH. Abstract 6540: Regression of metastatic cancer and abscopal effects following in situ vaccination by cryosurgical tumor cell lysis and intratumoral immunotherapy: A case series Cancer Research. 80: 6540-6540. DOI: 10.1158/1538-7445.Am2020-6540 |
0.419 |
|
| 2019 |
Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Georgetown, Tex.). 1-12. PMID 31318640 DOI: 10.1080/15384101.2019.1638693 |
0.527 |
|
| 2019 |
Bunch BL, Ma Y, Attwood K, Amable L, Luo W, Morrison C, Guru KA, Woloszynska-Read A, Hershberger PA, Trump DL, Johnson CS. Vitamin D enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk. Cancer Medicine. PMID 30972950 DOI: 10.1002/Cam4.2119 |
0.615 |
|
| 2019 |
Aragon-Ching JB, Trump DL, Wang H. Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis. Journal of Clinical Oncology. 37: 402-402. DOI: 10.1200/Jco.2019.37.7_Suppl.402 |
0.372 |
|
| 2018 |
Trump DL. Calcitriol and cancer therapy: A missed opportunity. Bone Reports. 9: 110-119. PMID 30591928 DOI: 10.1016/j.bonr.2018.06.002 |
0.377 |
|
| 2018 |
McDonnell SL, Baggerly CA, French CB, Baggerly LL, Garland CF, Gorham ED, Hollis BW, Trump DL, Lappe JM. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. Plos One. 13: e0199265. PMID 29906273 DOI: 10.1371/Journal.Pone.0199265 |
0.359 |
|
| 2018 |
Trump DL, Aragon-Ching JB. Vitamin D in prostate cancer. Asian Journal of Andrology. PMID 29667615 |
0.385 |
|
| 2018 |
Nizam A, Trump DL, Aragon-Ching JB. Molecular characterization of brain metastases in patients with metastatic urothelial cancer. Journal of Clinical Oncology. 36: 509-509. DOI: 10.1200/Jco.2018.36.6_Suppl.509 |
0.368 |
|
| 2018 |
Cannon TL, Murphy J, Carter J, Trump DL, Elkin SK, Asif A, Knopp L, Jessup JM. Impact of molecular tumor board on late-stage gastrointestinal malignancies at a tertiary center. Journal of Clinical Oncology. 36: 483-483. DOI: 10.1200/Jco.2018.36.4_Suppl.483 |
0.312 |
|
| 2018 |
Luo W, Ma Y, Cortes E, Omilian A, Bshara W, Azabdaftari G, Bunch B, Johnson C, Trump D. Abstract 4625: Tumor expression of PIM kinases in renal cell carcinoma and the association with disease progression Cancer Research. 78: 4625-4625. DOI: 10.1158/1538-7445.Am2018-4625 |
0.542 |
|
| 2017 |
Campbell MJ, Trump DL. Vitamin D Receptor Signaling and Cancer. Endocrinology and Metabolism Clinics of North America. 46: 1009-1038. PMID 29080633 DOI: 10.1016/j.ecl.2017.07.007 |
0.333 |
|
| 2017 |
Ma Y, Luo W, Bunch BL, Pratt RN, Trump DL, Johnson CS. 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget. 8: 60080-60093. PMID 28947955 DOI: 10.18632/Oncotarget.19629 |
0.575 |
|
| 2017 |
Ma Y, Luo W, Bunch BL, Pratt RN, Trump DL, Johnson CS. 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget. PMID 28778065 DOI: 10.18632/oncotarget.19629 |
0.52 |
|
| 2017 |
Aragon-Ching JB, Trump DL. Targeted therapies in the treatment of urothelial cancers. Urologic Oncology. PMID 28366271 DOI: 10.1016/J.Urolonc.2017.03.011 |
0.321 |
|
| 2017 |
Bunch BL, Trump D, Johnson CS. Abstract 1086: Vitamin D3 increases the response to cisplatin in bladder cancer through VDR and TAp73 pathway crosstalk Cancer Research. 77: 1086-1086. DOI: 10.1158/1538-7445.Am2017-1086 |
0.64 |
|
| 2016 |
Cannon TL, Ford J, Hester D, Trump DL. The Incidental Use of High-Dose Vitamin D3 in Pancreatic Cancer. Case Reports in Pancreatic Cancer. 2: 32-35. PMID 30631812 DOI: 10.1089/crpc.2016.0003 |
0.357 |
|
| 2016 |
Sundaram S, Finlay A, Romanova N, Knopp L, Pierattini C, Fuentes J, Hidalgo E, Daye M, Kokon M, Gustavson C, Radomsky P, Buras J, DeSimone J, Venna SS, Deeken JF, ... Trump DL, et al. Early discussion of advance directives for patients with newly diagnosed cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 91. PMID 28152813 DOI: 10.1200/Jco.2016.34.7_Suppl.91 |
0.3 |
|
| 2016 |
Wei L, Papanicolau-Sengos A, Liu S, Wang J, Conroy JM, Glenn ST, Brese E, Hu Q, Miles KM, Burgher B, Qin M, Head K, Omilian AR, Bshara W, Krolewski J, ... Trump DL, et al. Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing. Bmc Medical Genomics. 9: 64. PMID 27756300 DOI: 10.1186/S12920-016-0226-1 |
0.436 |
|
| 2016 |
Aragon-Ching JB, Trump DL. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. Future Oncology (London, England). PMID 27306417 DOI: 10.2217/Fon-2016-0155 |
0.342 |
|
| 2016 |
Luo W, Johnson CS, Trump DL. Vitamin D Signaling Modulators in Cancer Therapy. Vitamins and Hormones. 100: 433-72. PMID 26827962 DOI: 10.1016/Bs.Vh.2015.11.004 |
0.612 |
|
| 2016 |
Ma Y, Johnson CS, Trump DL. Mechanistic Insights of Vitamin D Anticancer Effects. Vitamins and Hormones. 100: 395-431. PMID 26827961 DOI: 10.1016/Bs.Vh.2015.11.003 |
0.628 |
|
| 2016 |
Trump D. Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11]. Urologic Oncology. 34: 247. PMID 25907623 DOI: 10.1016/J.Urolonc.2015.02.008 |
0.406 |
|
| 2016 |
Trump DL, Brady WE, Aragon-Ching JB, Pili R, Levine EG, George S, Johnson CS. A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer. Journal of Clinical Oncology. 34: 5065-5065. DOI: 10.1200/Jco.2016.34.15_Suppl.5065 |
0.631 |
|
| 2016 |
Luo W, Ma Y, Chernov M, Trump DL, Johnson CS. Abstract 866: Delineation of novel CYP24A1 transcriptional regulators Endocrinology. 76: 866-866. DOI: 10.1158/1538-7445.Am2016-866 |
0.444 |
|
| 2016 |
Steck SE, Woloszynska-Read A, Antwi S, Zhang H, Arab L, Fontham ETH, Mohler J, Su LJ, Xiao F, Smith G, Trump D, Johnson C, Bensen J. Abstract 806: SNPs in vitamin D-related genes are associated with prostate cancer aggressiveness in the North Carolina-Louisiana Prostate Cancer Project (PCaP) Epidemiology. 76: 806-806. DOI: 10.1158/1538-7445.Am2016-806 |
0.6 |
|
| 2016 |
Bunch BL, Johnson CS, Trump DL. Abstract 1190: Pretreatment with 1,25 dihydroxyvitamin D3 modulates p73 levels and activity to increase pro-apoptotic effects of cisplatin in bladder cancer Cancer Research. 76: 1190-1190. DOI: 10.1158/1538-7445.Am2016-1190 |
0.621 |
|
| 2015 |
Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, ... ... Trump DL, et al. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harbor Molecular Case Studies. 1: a000380. PMID 27148567 DOI: 10.1101/mcs.a000380 |
0.426 |
|
| 2015 |
Yao S, Haddad SA, Hu Q, Liu S, Lunetta KL, Ruiz-Narvaez EA, Hong CC, Zhu Q, Sucheston-Campbell L, David Cheng TY, Bensen JT, Johnson CS, Trump DL, Haiman CA, Olshan AF, et al. Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER Consortium. International Journal of Cancer. Journal International Du Cancer. PMID 26650177 DOI: 10.1002/Ijc.29954 |
0.571 |
|
| 2015 |
Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS. Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model. Cancer Prevention Research (Philadelphia, Pa.). PMID 26276745 DOI: 10.1158/1940-6207.Capr-14-0403 |
0.766 |
|
| 2015 |
Steck SE, Arab L, Zhang H, Bensen JT, Fontham ET, Johnson CS, Mohler JL, Smith GJ, Su JL, Trump DL, Woloszynska-Read A. Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. Plos One. 10: e0125151. PMID 25919866 DOI: 10.1371/Journal.Pone.0125151 |
0.589 |
|
| 2015 |
Liu B, Conroy JM, Morrison CD, Odunsi AO, Qin M, Wei L, Trump DL, Johnson CS, Liu S, Wang J. Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives. Oncotarget. 6: 5477-89. PMID 25849937 DOI: 10.18632/Oncotarget.3491 |
0.492 |
|
| 2015 |
Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, Liu S, Trump DL, Johnson CS. 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 148: 166-71. PMID 25263658 DOI: 10.1016/J.Jsbmb.2014.09.020 |
0.563 |
|
| 2015 |
Greenspan RD, Krishnan N, Morrison C, Omilian A, Bshara W, Worral A, Attwood K, Trump DL, Woloszynska-Read A, Johnson CS. Abstract LB-158: P73, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle invasive bladder cancer (MIBC) Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-158 |
0.56 |
|
| 2015 |
Bunch BL, Woloszynska-Read A, Trump DL, Johnson CS. Abstract LB-039: 1,25 dihydroxyvitamin D3 and cisplatin combination modulate p73 in bladder cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-039 |
0.6 |
|
| 2015 |
Iyer RV, Sexton S, Curtin L, Fetterly G, Maguire O, Minderman H, Toshkov I, Tennant B, Hutson A, Trump DL, Johnson C. Abstract 5144: Low dose sorafenib delays hepatocellular cancer (HCC) development in the woodchuck model of hepatitis B related HCC Cancer Research. 75: 5144-5144. DOI: 10.1158/1538-7445.Am2015-5144 |
0.507 |
|
| 2015 |
Ma Y, Luo W, Pratt R, Trump DL, Johnson CS. Abstract 5095: 1,25D3 inhibits migration and invasion through miR-101-3p in human bladder cancer cells Cancer Research. 75: 5095-5095. DOI: 10.1158/1538-7445.Am2015-5095 |
0.578 |
|
| 2015 |
Luo W, Ma Y, Baldino C, Caserta J, Ramakrishnan S, Roberto P, Johnson C, Trump D. Abstract 5056: PIM-1 kinase regulates vitamin D receptor signaling in human renal carcinoma cells Cancer Research. 75: 5056-5056. DOI: 10.1158/1538-7445.Am2015-5056 |
0.621 |
|
| 2014 |
Chadha KC, Miller A, Nair BB, Schwartz SA, Trump DL, Underwood W. New serum biomarkers for prostate cancer diagnosis. Clinical Cancer Investigation Journal. 3: 72-79. PMID 25593898 DOI: 10.4103/2278-0513.125802 |
0.353 |
|
| 2014 |
Ma Y, Trump DL, Johnson CS. Vitamin D and miRNAs in cancer. Current Gene Therapy. 14: 269-75. PMID 25039615 DOI: 10.2174/1566523214666140612153537 |
0.571 |
|
| 2014 |
Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, Foster BA. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. Plos One. 9: e89555. PMID 24586868 DOI: 10.1371/Journal.Pone.0089555 |
0.635 |
|
| 2014 |
Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget. 5: 824-40. PMID 24583788 DOI: 10.18632/Oncotarget.1776 |
0.492 |
|
| 2014 |
Yao S, Hong CC, McCann SE, Zirpoli G, Quan L, Gong Z, Johnson CS, Trump DL, Ambrosone CB. Combined effects of circulating levels of 25-hydroxyvitamin d and Th1 and th2 cytokines on breast cancer estrogen receptor status. Cancers. 6: 211-25. PMID 24473087 DOI: 10.3390/Cancers6010211 |
0.566 |
|
| 2014 |
Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, ... ... Trump DL, et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: E672-81. PMID 24469795 DOI: 10.1073/Pnas.1313580111 |
0.529 |
|
| 2014 |
Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, Wilding GE, Ford LA, Sait SN, Block AW, Adjei AA, Barcos M, Griffiths EA, Thompson JE, Wang ES, ... ... Trump DL, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 120: 521-9. PMID 24166051 DOI: 10.1002/Cncr.28368 |
0.553 |
|
| 2014 |
Ghani S, Attwood K, Elefante A, Khalid K, Trump DL. Evaluation of prostate specific antigen (PSA) response following abiraterone in metastatic, castration resistant prostate cancer (mCRPC) previously treated with ketoconazole compared to ketoconazole naïve patients: A retrospective review. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E16067 |
0.379 |
|
| 2014 |
Steck SE, Woloszynska-Read A, Arab L, McMahon D, Bensen J, Adams JS, Fontham ETH, Mohler JL, Su LJ, Zhang H, Trump D, Johnson C. Abstract B07: Ratio of plasma 1,25(OH)2D to 25(OH)D is inversely associated with aggressive prostate cancer in African Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP) Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-B07 |
0.629 |
|
| 2014 |
Chadha KC, Miller A, Nair BB, Schwartz SA, Trump DL, Underwood W. Abstract 879: New serum biomarkers for prostate cancer diagnosis Cancer Research. 74: 879-879. DOI: 10.1158/1538-7445.Am2014-879 |
0.368 |
|
| 2014 |
Luo W, Baldino CM, Caserta J, Ma Y, Johnson C, Trump DL. Abstract 607: Targeting PIM1 kinase enhances 1,25-dihydroxyvitamin D3-mediated anti-tumor activity in bladder cancer cells Cancer Research. 74: 607-607. DOI: 10.1158/1538-7445.Am2014-607 |
0.63 |
|
| 2014 |
Pomakov A, Toshkov I, Buitrago S, Curtin L, Trump D, Johnson C, Ashton E, Tennant B, Iyer R. Abstract 4946: Developing anti-angiogenic therapies for human hepatocellular cancer (HCC)- studies of suntinib in the woodchuck model of hepatitis B related HCC Cancer Research. 74: 4946-4946. DOI: 10.1158/1538-7445.Am2014-4946 |
0.499 |
|
| 2014 |
Mazzilli SA, Reid ME, Bogner PN, Attwood K, Hershberger PA, Trump DL, Johnson CS. Abstract 238: Vitamin D sufficiency slows the progression of dysplasic lesions in the NTCU mouse model of lung squamous cell carcinoma Cancer Research. 74: 238-238. DOI: 10.1158/1538-7445.Am2014-238 |
0.606 |
|
| 2014 |
Krishnan N, Woloszynska-Read A, Wang J, Liu S, Morrison C, Guru K, Smit E, Trump D, Johnson C. Abstract 2226: Loss of STAG2 in bladder cancer Cancer Research. 74: 2226-2226. DOI: 10.1158/1538-7445.Am2014-2226 |
0.557 |
|
| 2014 |
Pomakov A, Toshkov I, Buitrago S, Curtin L, Trump D, Johnson CS, Ashton E, Tennant B, Iyer R. Mo1927 Histological Changes Following Sunitinib Therapy in the Woodchuck Model of Hepatitis B Related HCC Gastroenterology. 146: S-693-S-694. DOI: 10.1016/S0016-5085(14)62517-8 |
0.44 |
|
| 2014 |
Den Haese JP, Frangou CG, Johnson CS, Trump DL, Wetzler M. 25(OH) Vitamin D3 Delays Leukemogenesis in an Acute Myeloid Leukemia Murine Model Clinical Lymphoma Myeloma and Leukemia. 14: S121-S122. DOI: 10.1016/J.Clml.2014.06.042 |
0.551 |
|
| 2013 |
Liu B, Morrison CD, Johnson CS, Trump DL, Qin M, Conroy JC, Wang J, Liu S. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget. 4: 1868-81. PMID 24240121 DOI: 10.18632/Oncotarget.1537 |
0.489 |
|
| 2013 |
Shen H, Morrison CD, Zhang J, Underwood W, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, ... ... Trump DL, et al. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 4: 2124-34. PMID 24231253 DOI: 10.18632/Oncotarget.1485 |
0.337 |
|
| 2013 |
Trump DL. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19. Urologic Oncology. 31: 1848. PMID 24210087 DOI: 10.1016/J.Urolonc.2013.07.012 |
0.369 |
|
| 2013 |
Rehman S, Crane A, Din R, Raza SJ, Shi Y, Wilding G, Levine EG, George S, Pili R, Trump DL, Guru KA. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology. 82: 1370-5. PMID 24125689 DOI: 10.1016/J.Urology.2013.07.055 |
0.339 |
|
| 2013 |
Luo W, Hu Q, Wang D, Deeb KK, Ma Y, Morrison CD, Liu S, Johnson CS, Trump DL. Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. Oncotarget. 4: 1472-83. PMID 23978847 DOI: 10.18632/Oncotarget.1269 |
0.548 |
|
| 2013 |
Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, ... ... Trump DL, et al. Penile cancer: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 594-615. PMID 23667209 DOI: 10.6004/Jnccn.2013.0075 |
0.334 |
|
| 2013 |
Muindi JR, Adjei AA, Wu ZR, Olson I, Huang H, Groman A, Tian L, Singh PK, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes. Hormones & Cancer. 4: 242-50. PMID 23456391 DOI: 10.1007/S12672-013-0139-9 |
0.584 |
|
| 2013 |
Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 71: 1173-82. PMID 23435876 DOI: 10.1007/S00280-013-2109-X |
0.566 |
|
| 2013 |
Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle (Georgetown, Tex.). 12: 743-52. PMID 23388458 DOI: 10.4161/Cc.23846 |
0.61 |
|
| 2013 |
Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Research. 73: 2289-97. PMID 23358686 DOI: 10.1158/0008-5472.Can-12-4119 |
0.63 |
|
| 2013 |
Luo W, Hershberger PA, Trump DL, Johnson CS. 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. The Journal of Steroid Biochemistry and Molecular Biology. 136: 252-7. PMID 23059474 DOI: 10.1016/J.Jsbmb.2012.09.031 |
0.613 |
|
| 2013 |
Ma Y, Yu WD, Su B, Seshadri M, Luo W, Trump DL, Johnson CS. Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol. Cancer. 119: 563-74. PMID 22833444 DOI: 10.1002/Cncr.27531 |
0.575 |
|
| 2013 |
Frangou CG, Den Haese J, Nowak N, Johnson CS, Trump D, Wetzler M. 25(OH) Vitamin D3 Affects Acute Myeloid Leukemia Cell Proliferation Blood. 122: 5026-5026. DOI: 10.1182/Blood.V122.21.5026.5026 |
0.6 |
|
| 2013 |
Woloszynska-Read A, Arab L, Adams J, Bensen JT, Fontham ET, Mohler JL, Su J, Tabung F, Zhang H, Trump DL, Johnson CS, Steck SE. Abstract LB-12: Plasma 25-hydroxyvitamin D levels are associated with aggressive prostate cancer among African Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-12 |
0.612 |
|
| 2013 |
Ma Y, Yu W, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL. Abstract 3434: Inecalcitol, an analogue of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cancer Research. 73: 3434-3434. DOI: 10.1158/1538-7445.Am2013-3434 |
0.63 |
|
| 2013 |
Luo W, Chernov M, Ma Y, Johnson C, Trump D. Abstract 1819: Over-expression of PIM1 kinase contributes to CYP24A1 gene up-regulation in prostate cancer. Cancer Research. 73: 1819-1819. DOI: 10.1158/1538-7445.Am2013-1819 |
0.55 |
|
| 2013 |
Mazzilli SA, Reid M, Bogner P, Trump D, Johnson C. Abstract 178: Vitamin D reduces lung cancer progression the N-nitroso-tris-chloroethylurea model of mouse lung squamous cell carcinoma. Cancer Research. 73: 178-178. DOI: 10.1158/1538-7445.Am2013-178 |
0.79 |
|
| 2013 |
Aboumohamed A, Rehman S, Crane A, Stegemann A, Din R, Shi Y, Wilding G, Levine E, George S, Trump D, Guru K. 1437 UNDERSTANDING AVOIDANCE, REFUSAL AND ABANDONMENT OF CHEMOTHERAPY BEFORE AND AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2791 |
0.318 |
|
| 2012 |
Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R. A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 318. PMID 27968059 DOI: 10.1200/Jco.2012.30.5_Suppl.318 |
0.307 |
|
| 2012 |
Trump DL. Commentary on "comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial." B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D. Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim, R.J. Motzer: Lancet 2011;378:1931-9 [Epub;2011, November 4]. Urologic Oncology. 30: 748. PMID 23021562 DOI: 10.1016/J.Urolonc.2012.06.009 |
0.318 |
|
| 2012 |
Trump DL. Commentary on "duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer." A.V. D'Amico, M.H. Chen, J. Crook, J.G. Armstrong, S. Malone, A. Steigler, M. Dunne, P.W. Kantoff, J.W. Denham, Brigham and Women's Hospital, Boston, MA. 02115, USA.: J Clin Oncol 2011;29:4682-7. Urologic Oncology. 30: 746. PMID 23021560 DOI: 10.1016/J.Urolonc.2012.06.006 |
0.344 |
|
| 2012 |
Trump DL. Commentary on "association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials." Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA: JAMA 2011;306(21):2359-66. Urologic Oncology. 30: 746-7. PMID 23021559 DOI: 10.1016/J.Urolonc.2012.06.007 |
0.376 |
|
| 2012 |
Trump DL. Commentary on "surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localized or locally advanced prostate cancer: an analysis of 2 randomized trials." A.V. D'Amico, M.H. Chen, M. de Castro, M. Loffredo, D.S. Lamb, A. Steigler, P.W. Kantoff, J.W. Denham, Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA: Lancet Oncol 2012;13:189-95 [Epub;2011, November 21]. Urologic Oncology. 30: 745. PMID 23021558 DOI: 10.1016/J.Urolonc.2012.06.005 |
0.409 |
|
| 2012 |
Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Rheumatic Diseases Clinics of North America. 38: 161-78. PMID 22525850 DOI: 10.1016/J.Rdc.2012.03.014 |
0.605 |
|
| 2012 |
Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, Sucheston LE, Tang L, Roberts M, Ciupak G, Davis W, Hwang H, Johnson CS, Trump DL, McCann SE, et al. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Research : Bcr. 14: R58. PMID 22480149 DOI: 10.1186/Bcr3162 |
0.555 |
|
| 2012 |
Yoo J, Olson I, Muindi J, Iyer R, Attwood K, Johnson C, Trump D. Serum and Bile 25(OH)D3 and 1,25(OH)2D3 Levels in Patients with Cancers Affecting the Gall Bladder and Biliary Duct: 232 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-00232 |
0.6 |
|
| 2012 |
Ramnath N, Daignault-Newton S, Dy GK, Muindi J, Adjei A, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Johnson CS, Trump DL. A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18118 |
0.564 |
|
| 2012 |
Singh PK, Hu Q, Yan L, Liu S, Trump DL, Sucheston LE, Campbell MJ. Abstract LB-477: Micro-RNA expression patterns to classify prostate cancer risk Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-477 |
0.305 |
|
| 2012 |
Luo W, Deeb KK, Liu S, Ma Y, Morrison CD, Trump DL, Johnson CS. Abstract 4280: Genome-wide expression and methylation analysis in CD31+ cells from African American and Caucasian American benign and malignant prostate tissue Cancer Research. 72: 4280-4280. DOI: 10.1158/1538-7445.Am2012-4280 |
0.558 |
|
| 2012 |
Mazzilli SA, Reid ME, Seshadri M, Bogner PN, Foster BA, Johnson CS, Trump DL. Abstract 1606: Antitumor effects of vitamin D in a carcinogen-induced mouse model of lung cancer Cancer Research. 72: 1606-1606. DOI: 10.1158/1538-7445.Am2012-1606 |
0.792 |
|
| 2012 |
Woloszynska-Read A, Wang D, Liu S, Mohler JL, Trump DL, Johnson CS. Abstract B33: Genome-wide methylation analyses reveal racial differences in blood DNA of prostate cancer patients from the North Carolina-Louisiana Prostate Cancer Project (PCaP) cohort. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B33 |
0.552 |
|
| 2011 |
Trump DL, Al-Hussaini MH, Silliman C, Jarkowski A, Johnson CS. Effect of ketoconazole/hydrocortisone (Keto/HC) on 25 (OH) vitamin D in men with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13063. PMID 28019888 DOI: 10.1200/Jco.2011.29.15_Suppl.E13063 |
0.615 |
|
| 2011 |
Al-Hussaini MH, Johnson CS, Muindi J, Chadha MK, Silliman C, Tian L, Tan W, Nesline M, Sandecki A, Kuettel MR, Mohler J, Guru K, Trump DL. Serum 25(OH) vitamin D3 response to vitamin D3 supplementation in men with prostate cancer: Results of a randomized phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13060. PMID 28019887 DOI: 10.1200/Jco.2011.29.15_Suppl.E13060 |
0.641 |
|
| 2011 |
Wakshlag JJ, Rassnick KM, Malone EK, Struble AM, Vachhani P, Trump DL, Tian L. Cross-sectional study to investigate the association between vitamin D status and cutaneous mast cell tumours in Labrador retrievers. The British Journal of Nutrition. 106: S60-3. PMID 22005438 DOI: 10.1017/S000711451100211X |
0.419 |
|
| 2011 |
Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Practice & Research. Clinical Endocrinology & Metabolism. 25: 605-15. PMID 21872802 DOI: 10.1016/J.Beem.2011.06.006 |
0.624 |
|
| 2011 |
Hidalgo AA, Deeb KK, Pike JW, Johnson CS, Trump DL. Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription. The Journal of Biological Chemistry. 286: 36228-37. PMID 21868377 DOI: 10.1074/Jbc.M111.244061 |
0.573 |
|
| 2011 |
Hidalgo AA, Montecinos VP, Paredes R, Godoy AS, McNerney EM, Tovar H, Pantoja D, Johnson C, Trump D, Onate SA. Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment. Biochemical and Biophysical Research Communications. 412: 13-9. PMID 21763285 DOI: 10.1016/J.Bbrc.2011.06.181 |
0.597 |
|
| 2011 |
Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics : Official Journal of the Dna Methylation Society. 6: 994-1000. PMID 21725204 DOI: 10.4161/Epi.6.8.16536 |
0.496 |
|
| 2011 |
Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H, Kulkarni S, Edge SB, O'Connor TL, Ambrosone CB. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. Plos One. 6: e17251. PMID 21386992 DOI: 10.1371/Journal.Pone.0017251 |
0.563 |
|
| 2011 |
Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, Mustian KM, Janelsins MC, Purnell JQ, Morrow GR. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Research and Treatment. 127: 171-7. PMID 21384167 DOI: 10.1007/S10549-011-1415-4 |
0.452 |
|
| 2011 |
Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA, Nathan F, Taboada M, Morris T, Hubner A. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The Prostate. 71: 1264-75. PMID 21271613 DOI: 10.1002/Pros.21342 |
0.385 |
|
| 2011 |
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). Bju International. 108: 693-9. PMID 21105991 DOI: 10.1111/J.1464-410X.2010.09900.X |
0.315 |
|
| 2011 |
Chadha MK, Fakih M, Muindi J, Tian L, Mashtare T, Johnson CS, Trump D. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. The Prostate. 71: 368-72. PMID 20812224 DOI: 10.1002/Pros.21250 |
0.563 |
|
| 2011 |
Jain RK, Trump DL, Egorin MJ, Fernandez M, Johnson CS, Ramanathan RK. A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors. Investigational New Drugs. 29: 1420-5. PMID 20661623 DOI: 10.1007/S10637-010-9492-5 |
0.609 |
|
| 2011 |
Rassnick KM, Muindi JR, Johnson CS, Bailey DB, Trump DL. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. Cancer Chemotherapy and Pharmacology. 67: 165-71. PMID 20306264 DOI: 10.1007/S00280-010-1304-2 |
0.522 |
|
| 2011 |
Luo W, Karpf AR, Chernov MC, Johnson C, Trump D. Abstract 942: Protein kinase CK2 contributes to 1, 25-dihydroxyvitamin D3-mediated CYP24A1 gene expression in prostate cancer cells Cancer Research. 71: 942-942. DOI: 10.1158/1538-7445.Am2011-942 |
0.645 |
|
| 2011 |
Ma Y, Yu W, Kong R, Delansorne R, Trump DL, Johnson CS. Abstract 583: Inecalcitol, a 14-epi-analogue of 1,25D3, induces growth inhibition through apoptosis and cell cycle arrest in a squamous cell carcinoma model system Cancer Research. 71: 583-583. DOI: 10.1158/1538-7445.Am2011-583 |
0.619 |
|
| 2011 |
Woloszynska-Read A, Tian L, Mohler JL, Fontham ET, Bensen JT, Johnson CS, Trump DL. Abstract B81: Vitamin D and prostate cancer aggressiveness among African and European Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP) case study cohort Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-B81 |
0.643 |
|
| 2011 |
Trump DL. Commentary on “Sipuleucel-T immunotherapy for castration-resistant prostate cancer”. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA : Collaborators (84) Urologic Oncology-Seminars and Original Investigations. 29: 230-231. DOI: 10.1016/J.Urolonc.2011.01.012 |
0.308 |
|
| 2011 |
Trump DL. Commentary on “Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer”. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS, Massachusetts General Hospital Cancer Center, Boston, MA Urologic Oncology-Seminars and Original Investigations. 29: 230. DOI: 10.1016/J.Urolonc.2011.01.011 |
0.365 |
|
| 2011 |
Trump DL. Commentary on “Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study”. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX Urologic Oncology-Seminars and Original Investigations. 29: 228. DOI: 10.1016/J.Urolonc.2011.01.009 |
0.392 |
|
| 2010 |
Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. Journal of Cancer. 1: 101-7. PMID 20842231 DOI: 10.7150/Jca.1.101 |
0.585 |
|
| 2010 |
Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle (Georgetown, Tex.). 9: 3022-9. PMID 20699664 DOI: 10.4161/Cc.9.15.12381 |
0.538 |
|
| 2010 |
Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Veterinary and Comparative Oncology. 8: 209-20. PMID 20691028 DOI: 10.1111/J.1476-5829.2010.00223.X |
0.533 |
|
| 2010 |
Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, Johnson CS. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 151: 4301-12. PMID 20591973 DOI: 10.1210/En.2009-1156 |
0.548 |
|
| 2010 |
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Research. 70: 5953-62. PMID 20587525 DOI: 10.1158/0008-5472.Can-10-0617 |
0.587 |
|
| 2010 |
Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer. 116: 3294-303. PMID 20564622 DOI: 10.1002/Cncr.25059 |
0.613 |
|
| 2010 |
Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinology and Metabolism Clinics of North America. 39: 401-18, table of con. PMID 20511060 DOI: 10.1016/J.Ecl.2010.02.011 |
0.629 |
|
| 2010 |
Hidalgo AA, Trump DL, Johnson CS. Glucocorticoid regulation of the vitamin D receptor. The Journal of Steroid Biochemistry and Molecular Biology. 121: 372-5. PMID 20398752 DOI: 10.1016/J.Jsbmb.2010.03.081 |
0.569 |
|
| 2010 |
Johnson CS, Chung I, Trump DL. Epigenetic silencing of CYP24 in the tumor microenvironment. The Journal of Steroid Biochemistry and Molecular Biology. 121: 338-42. PMID 20304059 DOI: 10.1016/J.Jsbmb.2010.03.046 |
0.56 |
|
| 2010 |
Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 116: 2132-9. PMID 20166215 DOI: 10.1002/Cncr.24973 |
0.56 |
|
| 2010 |
Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer Journal (Sudbury, Mass.). 16: 1-9. PMID 20164683 DOI: 10.1097/Ppo.0B013E3181C51Ee6 |
0.649 |
|
| 2010 |
Iyer RV, Fetterly GJ, Javle MM, Tan W, Wilding GE, Muindi J, Fakih M, Ramnath N, Johnson CS, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. Journal of Clinical Oncology. 28: e13031-e13031. DOI: 10.1200/Jco.2010.28.15_Suppl.E13031 |
0.518 |
|
| 2010 |
Trump DL, Payne H, Miller K, Bono JSD, Stephenson J, Burris HA, Nathan FE, Taboada M, Morris T, Hubner A. Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety. Journal of Clinical Oncology. 28: 4664-4664. DOI: 10.1200/Jco.2010.28.15_Suppl.4664 |
0.383 |
|
| 2010 |
Lee HJ, Muindi J, Wei T, Wilding G, Ford LA, Sait S, Block A, Barcos M, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Johnson CS, Trump D, Wetzler M. Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients. Blood. 116: 1041-1041. DOI: 10.1182/Blood.V116.21.1041.1041 |
0.583 |
|
| 2010 |
Muindi JRF, Adjei AA, Wu ZR, Tian L, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Abstract 82: A comprehensive characterization of cholecalciferol supplementation induced changes in the vitamin D3metabolic pathway in metastatic colorectal cancer patients Cancer Research. 70: 82-82. DOI: 10.1158/1538-7445.Am10-82 |
0.589 |
|
| 2010 |
Ma Y, Su B, Yu W, Seshadri M, Turowski SG, Kong R, Gillard BM, Trump DL, Johnson CS. Abstract 5123: 1,25D3regulates cell-matrix and cell-cell adhesion and reduces experimental metastasis in a squamous cell carcinoma model system Cancer Research. 70: 5123-5123. DOI: 10.1158/1538-7445.Am10-5123 |
0.598 |
|
| 2010 |
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Trump DL, Johnson CS. Abstract 4944: Regulation of vitamin D 24-hydroxylase gene expression in human prostate cancer by epigenetic mechanisms Cancer Research. 70: 4944-4944. DOI: 10.1158/1538-7445.Am10-4944 |
0.611 |
|
| 2010 |
Mazzilli SA, Reid ME, Foster BA, Johnson CS, Trump DL. Abstract 1898: The effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on the tumorigenesis of lung squamous cell carcinoma Cancer Research. 70: 1898-1898. DOI: 10.1158/1538-7445.Am10-1898 |
0.77 |
|
| 2010 |
Deeb KK, Liu S, Luo W, Karpf AR, Morrison C, Johnson CS, Trump DL. Abstract 1288: Molecular features of endothelial cells isolated from benign and malignant prostatic tissues Cancer Research. 70: 1288-1288. DOI: 10.1158/1538-7445.Am10-1288 |
0.507 |
|
| 2009 |
Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL. Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e20575. PMID 27961109 DOI: 10.1200/Jco.2009.27.15_Suppl.E20575 |
0.384 |
|
| 2009 |
Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford ED. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 115: 4104-9. PMID 19517476 DOI: 10.1002/Cncr.24466 |
0.313 |
|
| 2009 |
Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, Hollis BW, Nesline MK, Tian L, Tan W, Johnson CS. Vitamin D deficiency and insufficiency among patients with prostate cancer. Bju International. 104: 909-14. PMID 19426195 DOI: 10.1111/J.1464-410X.2009.08531.X |
0.629 |
|
| 2009 |
Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65: 33-40. PMID 19396601 DOI: 10.1007/S00280-009-1000-2 |
0.507 |
|
| 2009 |
Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research. 69: 967-75. PMID 19141646 DOI: 10.1158/0008-5472.Can-08-2307 |
0.538 |
|
| 2009 |
Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. The Journal of Urology. 181: 621-6. PMID 19091347 DOI: 10.1016/J.Juro.2008.10.014 |
0.381 |
|
| 2009 |
Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. International Journal of Colorectal Disease. 24: 219-24. PMID 18830610 DOI: 10.1007/S00384-008-0593-Y |
0.617 |
|
| 2009 |
Trump DL. Commentary on Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer Urologic Oncology-Seminars and Original Investigations. 27: 574-575. DOI: 10.1016/J.Urolonc.2009.07.011 |
0.383 |
|
| 2009 |
Trump DL. Commentary on Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma Urologic Oncology-Seminars and Original Investigations. 27: 573. DOI: 10.1016/J.Urolonc.2009.07.009 |
0.307 |
|
| 2009 |
Trump DL. Commentary on Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Urologic Oncology: Seminars and Original Investigations. 27: 573. DOI: 10.1016/J.Urolonc.2009.07.008 |
0.303 |
|
| 2009 |
Trump DL. Commentary on Randomized phase II trial of first-line treatment with sorafenib vs. interferonα-2a in patients with metastatic renal cell carcinoma Urologic Oncology-Seminars and Original Investigations. 27: 572. DOI: 10.1016/J.Urolonc.2009.07.007 |
0.304 |
|
| 2009 |
Trump DL. Commentary on Bevacizumab plus interferonα compared with interferonα monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 Urologic Oncology-Seminars and Original Investigations. 27: 571-572. DOI: 10.1016/J.Urolonc.2009.07.006 |
0.305 |
|
| 2009 |
Trump DL. Commentary on A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation Urologic Oncology-Seminars and Original Investigations. 27: 571. DOI: 10.1016/J.Urolonc.2009.07.005 |
0.383 |
|
| 2008 |
Chadha MK, Ashraf U, Payne V, Silliman C, Escott P, Lawrence D, Tian L, Levine E, Trump DL. Phase II trial of fulvestrant in castration resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 16079. PMID 27947538 DOI: 10.1200/Jco.2008.26.15_Suppl.16079 |
0.383 |
|
| 2008 |
Lau YK, Chadha MK, Litwin A, Trump DL. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. Journal of Hematology & Oncology. 1: 21. PMID 18986533 DOI: 10.1186/1756-8722-1-21 |
0.354 |
|
| 2008 |
Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4426-34. PMID 18802155 DOI: 10.1200/Jco.2007.15.1233 |
0.343 |
|
| 2008 |
Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Molecular Cancer Therapeutics. 7: 3047-55. PMID 18790784 DOI: 10.1158/1535-7163.Mct-08-0243 |
0.621 |
|
| 2008 |
Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C, Escott P, Payne V, Trump DL. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. The Prostate. 68: 1461-6. PMID 18618738 DOI: 10.1002/Pros.20813 |
0.389 |
|
| 2008 |
Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ. Phenotype-specific CpG island methylation events in a murine model of prostate cancer. Cancer Research. 68: 4173-82. PMID 18519676 DOI: 10.1158/0008-5472.Can-07-6715 |
0.358 |
|
| 2008 |
Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu WD, Engler KL, Page RL, Trump DL. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemotherapy and Pharmacology. 62: 881-91. PMID 18246349 DOI: 10.1007/S00280-008-0678-X |
0.532 |
|
| 2008 |
Shah SK, Trump D, Wilding GE, Sartor O, Mohler JL. Phase Ii Clinical Trial Of Dutasteride In Castration- Recurrent Prostate Cancer The Journal of Urology. 179: 180-181. DOI: 10.1016/S0022-5347(08)60523-6 |
0.364 |
|
| 2008 |
Trump DL. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: A randomized Phase III clinical trial Urologic Oncology-Seminars and Original Investigations. 26: 564. DOI: 10.1016/J.Urolonc.2008.07.021 |
0.303 |
|
| 2008 |
Trump DL. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide, and cisplatin chemotherapy for high risk clinical Stage I nonseminomatous germ cell tumors of the testis Urologic Oncology-Seminars and Original Investigations. 26: 563-564. DOI: 10.1016/J.Urolonc.2008.07.020 |
0.326 |
|
| 2008 |
Trump DL. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer Urologic Oncology-Seminars and Original Investigations. 26: 563. DOI: 10.1016/J.Urolonc.2008.07.019 |
0.381 |
|
| 2008 |
Trump DL. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel Urologic Oncology-Seminars and Original Investigations. 26: 562-563. DOI: 10.1016/J.Urolonc.2008.07.018 |
0.379 |
|
| 2008 |
Trump DL. Randomized Phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical Stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German testicular cancer study group Urologic Oncology-Seminars and Original Investigations. 26: 561. DOI: 10.1016/J.Urolonc.2008.07.016 |
0.318 |
|
| 2007 |
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews. Cancer. 7: 684-700. PMID 17721433 DOI: 10.1038/Nrc2196 |
0.603 |
|
| 2007 |
Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Annals of Internal Medicine. 146: 416-24. PMID 17371886 DOI: 10.7326/0003-4819-146-6-200703200-00006 |
0.319 |
|
| 2007 |
Chung I, Yu WD, Karpf AR, Flynn G, Bernardi RJ, Modzelewski RA, Johnson CS, Trump DL. Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments. The Journal of Steroid Biochemistry and Molecular Biology. 103: 768-70. PMID 17368191 DOI: 10.1016/J.Jsbmb.2006.12.042 |
0.555 |
|
| 2007 |
Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL, Onate SA. Altered VDR-mediated transcriptional activity in prostate cancer stroma. The Journal of Steroid Biochemistry and Molecular Biology. 103: 731-6. PMID 17368189 DOI: 10.1016/J.Jsbmb.2006.12.072 |
0.583 |
|
| 2007 |
Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. The Journal of Steroid Biochemistry and Molecular Biology. 103: 334-7. PMID 17368180 DOI: 10.1016/J.Jsbmb.2006.12.060 |
0.556 |
|
| 2007 |
Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1216-23. PMID 17317832 DOI: 10.1158/1078-0432.Ccr-06-1165 |
0.429 |
|
| 2007 |
Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of Vitamin D insensitive prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 103: 712-6. PMID 17280828 DOI: 10.1016/J.Jsbmb.2006.12.008 |
0.638 |
|
| 2007 |
Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. The Journal of Biological Chemistry. 282: 8704-14. PMID 17244627 DOI: 10.1074/Jbc.M608894200 |
0.553 |
|
| 2007 |
Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA. Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells Oncology. 70: 483-492. PMID 17237623 DOI: 10.1159/000098813 |
0.618 |
|
| 2007 |
Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemotherapy and Pharmacology. 59: 581-7. PMID 17066293 DOI: 10.1007/S00280-006-0299-1 |
0.557 |
|
| 2007 |
Muindi JR, Peng Y, Wilson JW, Johnson CS, Branch RA, Trump DL. Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients. Cancer Chemotherapy and Pharmacology. 59: 97-104. PMID 16680461 DOI: 10.1007/S00280-006-0247-0 |
0.511 |
|
| 2007 |
Day R, Mohanty S, Bisceglia M, Acquafondata M, Dhir R, Becich M, Trump D, Nelson J. Randomized trial of toremifene to reduce high grade prostatic intraepithelial neoplasia (HGPIN) prior to radical prostatectomy (RP) Journal of Clinical Oncology. 25: 5150-5150. DOI: 10.1200/Jco.2007.25.18_Suppl.5150 |
0.313 |
|
| 2007 |
Trump DL. 1. Sorafenib in advanced clear-cell renal-cell carcinoma Urologic Oncology-Seminars and Original Investigations. 25: 443-445. DOI: 10.1016/J.Urolonc.2007.08.008 |
0.331 |
|
| 2007 |
Trump DL. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators Urologic Oncology-Seminars and Original Investigations. 25: 445-446. DOI: 10.1016/J.Urolonc.2007.08.007 |
0.397 |
|
| 2007 |
Trump DL. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR, Division of Hematology and Oncology and Endocrine Unit, Massachusetts General Hospital, Boston, MA Urologic Oncology-Seminars and Original Investigations. 25: 446. DOI: 10.1016/J.Urolonc.2007.08.006 |
0.327 |
|
| 2006 |
Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology. 70: 447-57. PMID 17237620 DOI: 10.1159/000098872 |
0.556 |
|
| 2006 |
Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, ... Trump DL, et al. Bladder cancer. Clinical guidelines in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 4: 984-1014. PMID 17112448 DOI: 10.6004/Jnccn.2006.0083 |
0.334 |
|
| 2006 |
Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Research. 66: 8565-73. PMID 16951169 DOI: 10.1158/0008-5472.Can-06-0905 |
0.577 |
|
| 2006 |
Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Research. 66: 8131-8. PMID 16912191 DOI: 10.1158/0008-5472.Can-06-1333 |
0.594 |
|
| 2006 |
Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Research. 26: 2551-6. PMID 16886663 |
0.611 |
|
| 2006 |
Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Research. 26: 2543-9. PMID 16886662 |
0.519 |
|
| 2006 |
Zmuda JM, Modugno F, Weissfeld JL, Cauley JA, Trump DL, Moffett SP, Ferrell RE. Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. Oncology. 70: 185-9. PMID 16763406 DOI: 10.1159/000093805 |
0.378 |
|
| 2006 |
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet. Oncology. 7: 472-9. PMID 16750497 DOI: 10.1016/S1470-2045(06)70700-8 |
0.375 |
|
| 2006 |
Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). The Prostate. 66: 1070-5. PMID 16637076 DOI: 10.1002/Pros.20329 |
0.413 |
|
| 2006 |
Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 106: 2136-42. PMID 16598750 DOI: 10.1002/Cncr.21890 |
0.591 |
|
| 2006 |
Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemotherapy and Pharmacology. 57: 465-74. PMID 16133531 DOI: 10.1007/S00280-005-0071-Y |
0.321 |
|
| 2006 |
Trump D, Javle M, Muindi J, Pendyala L, Yu W, Ramnath N, Ross M, Fakih M, Iyer R, Johnson C. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] in combination with gemcitabine [2’,2’ difluorodeoxycytidine] in patients with advanced malignancies Journal of Clinical Oncology. 24: 12010-12010. DOI: 10.1200/Jco.2006.24.18_Suppl.12010 |
0.504 |
|
| 2006 |
Chanan-Khan AA, Romano M, Pera P, Ersing N, Muindi J, Trump DL, Johnson C. Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma Cell Line (HMCL). Blood. 108: 5074-5074. DOI: 10.1182/Blood.V108.11.5074.5074 |
0.597 |
|
| 2006 |
Conroy T, Marchal F, Blazeby JM, Matsubara T, Shintani K, Wakabayashi T, Matsumine A, Uchida A, Chung I, Romano M, Modzelewski RA, Johnson CS, Trump DL, Raderer M, Wöhrer S, et al. Contents Vol. 70, 2006 Oncology. 70: 503-506. DOI: 10.1159/000100118 |
0.409 |
|
| 2006 |
Conroy T, Marchal F, Blazeby JM, Matsubara T, Shintani K, Wakabayashi T, Matsumine A, Uchida A, Chung I, Romano M, Modzelewski RA, Johnson CS, Trump DL, Raderer M, Wöhrer S, et al. Subject Index Vol. 70, 2006 Oncology. 70: 500-502. DOI: 10.1159/000100117 |
0.408 |
|
| 2006 |
Greenspan SL, Resnick NM, Nelson JB, Trump DL, Parker RA. 975: Once Weekly Oral Alendronate Prevents Bone Loss in Men on Androgen Deprivation Therapy for Prostate Cancer The Journal of Urology. 175: 314-315. DOI: 10.1016/S0022-5347(18)33200-2 |
0.359 |
|
| 2005 |
Hussain M, Petrylak D, Dunn R, Vaishampayan U, Lara PN, Chatta G, Nanus D, Glode LM, Trump D, Chen H, Smith DC. Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4507. PMID 27946524 DOI: 10.1200/Jco.2005.23.16_Suppl.4507 |
0.332 |
|
| 2005 |
Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 90: 6410-7. PMID 16189261 DOI: 10.1210/Jc.2005-0183 |
0.339 |
|
| 2005 |
Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. The Journal of Urology. 174: 753-6. PMID 16006970 DOI: 10.1097/01.Ju.0000168723.42824.40 |
0.357 |
|
| 2005 |
Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemotherapy and Pharmacology. 56: 492-6. PMID 15918041 DOI: 10.1007/S00280-005-1015-2 |
0.557 |
|
| 2005 |
Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, Herman-Antosiewicz A. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. The Journal of Biological Chemistry. 280: 19911-24. PMID 15764812 DOI: 10.1074/Jbc.M412443200 |
0.555 |
|
| 2005 |
Trump DL. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer Urologic Oncology-Seminars and Original Investigations. 23: 377. DOI: 10.1016/J.Urolonc.2005.06.018 |
0.382 |
|
| 2005 |
Trump DL. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group Urologic Oncology-Seminars and Original Investigations. 23: 378-379. DOI: 10.1016/J.Urolonc.2005.06.017 |
0.414 |
|
| 2005 |
Trump DL. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases Urologic Oncology-Seminars and Original Investigations. 23: 379. DOI: 10.1016/J.Urolonc.2005.06.014 |
0.322 |
|
| 2005 |
Trump DL. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study Urologic Oncology-Seminars and Original Investigations. 23: 381-382. DOI: 10.1016/J.Urolonc.2005.06.013 |
0.336 |
|
| 2005 |
Trump DL. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells Urologic Oncology: Seminars and Original Investigations. 23: 379-380. DOI: 10.1016/J.Urolonc.2005.06.012 |
0.383 |
|
| 2005 |
Trump DL. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo Urologic Oncology: Seminars and Original Investigations. 23: 380-381. DOI: 10.1016/J.Urolonc.2005.06.009 |
0.381 |
|
| 2005 |
Trump DL. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium Urologic Oncology-Seminars and Original Investigations. 23: 380. DOI: 10.1016/J.Urolonc.2005.06.008 |
0.341 |
|
| 2004 |
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Kiernan M, Trump D. Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4570. PMID 28015974 DOI: 10.1200/Jco.2004.22.14_Suppl.4570 |
0.356 |
|
| 2004 |
Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5058-64. PMID 15297407 DOI: 10.1158/1078-0432.Ccr-03-0288 |
0.334 |
|
| 2004 |
Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. The Prostate. 60: 303-9. PMID 15264241 DOI: 10.1002/Pros.20072 |
0.408 |
|
| 2004 |
Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. The Journal of Steroid Biochemistry and Molecular Biology. 89: 519-26. PMID 15225831 DOI: 10.1016/J.Jsbmb.2004.03.068 |
0.626 |
|
| 2004 |
Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ, Singh SV. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene. 23: 5594-606. PMID 15184882 DOI: 10.1038/Sj.Onc.1207747 |
0.543 |
|
| 2004 |
Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. The Prostate. 60: 178-86. PMID 15176047 DOI: 10.1002/Pros.20045 |
0.545 |
|
| 2004 |
Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Molecular Cancer Therapeutics. 3: 567-75. PMID 15141014 |
0.466 |
|
| 2004 |
Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology. 66: 62-6. PMID 15031600 DOI: 10.1159/000076336 |
0.557 |
|
| 2004 |
Avery R, Trump DL, Byock I, Miles SH. Hospice Benefits and Phase I Cancer Trials [5] (multiple letters) Annals of Internal Medicine. 140: 70-71. PMID 14706984 DOI: 10.7326/0003-4819-140-1-200401060-00028 |
0.327 |
|
| 2004 |
Hoffman LJ, Bunker CH, Pellett PE, Trump DL, Patrick AL, Dollard SC, Keenan HA, Jenkins FJ. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. The Journal of Infectious Diseases. 189: 15-20. PMID 14702148 DOI: 10.1086/380568 |
0.387 |
|
| 2004 |
Lau Y, Trump DL, Johnson C. Interaction of vitamin D receptor and androgen receptor in human prostate cancer cell line Journal of Clinical Oncology. 22: 9550-9550. DOI: 10.1200/JCO.2004.22.90140.9550 |
0.311 |
|
| 2004 |
Trump DL. Mortality after cure of testicular seminoma. Zagars GK, Ballo MT, Lee AK, Strom SS, Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.: J Clin Oncol 2004;22:640–7 Urologic Oncology-Seminars and Original Investigations. 22: 431-431. DOI: 10.1016/S1078-1439(04)00144-9 |
0.331 |
|
| 2004 |
Trump DL. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR, Department of Medicine, University of New South Wales, St. George Hospital Campus, Sydney, Australia.: Cancer 2004;100:892–9 Urologic Oncology-Seminars and Original Investigations. 22: 436-436. DOI: 10.1016/J.Urolonc.2004.07.010 |
0.332 |
|
| 2004 |
Trump DL. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH, Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.: J Natl Cancer Inst 2004;96:509–15 Urologic Oncology-Seminars and Original Investigations. 22: 435-436. DOI: 10.1016/J.Urolonc.2004.07.009 |
0.358 |
|
| 2004 |
Trump DL. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R, Department of Pathology and Laboratory Medicine, University of Florida, Gainesville, FL.: Cancer 2004;100:294–9 Urologic Oncology-Seminars and Original Investigations. 22: 435-435. DOI: 10.1016/J.Urolonc.2004.07.008 |
0.369 |
|
| 2004 |
Trump DL. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D, Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda, MD.: J Urol 2004;171:1141–7 Urologic Oncology-Seminars and Original Investigations. 22: 434-434. DOI: 10.1016/J.Urolonc.2004.07.007 |
0.315 |
|
| 2004 |
Trump DL. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H, Department of Urology, Graduate School of Medicine, Chiba University, Japan.: J Urol 2004;171:679–83 Urologic Oncology-Seminars and Original Investigations. 22: 433-434. DOI: 10.1016/J.Urolonc.2004.07.006 |
0.32 |
|
| 2004 |
Trump DL. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.: J Clin Oncol 2004;22:1025–33 Urologic Oncology-Seminars and Original Investigations. 22: 433-433. DOI: 10.1016/J.Urolonc.2004.07.005 |
0.337 |
|
| 2004 |
Trump DL. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.: J Clin Oncol 2004;22:454–63 Urologic Oncology-Seminars and Original Investigations. 22: 432-433. DOI: 10.1016/J.Urolonc.2004.07.004 |
0.307 |
|
| 2004 |
Trump DL. Mortality after cure of testicular seminoma. Zagars GK, Ballo MT, Lee AK, Strom SS, Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Urologic Oncology-Seminars and Original Investigations. 22: 431. DOI: 10.1016/J.Urolonc.2004.07.003 |
0.358 |
|
| 2003 |
Patel A, Coates PS, Nelson JB, Trump DL, Resnick NM, Greenspan SL. Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? Journal of Clinical Densitometry : the Official Journal of the International Society For Clinical Densitometry. 6: 323-30. PMID 14716044 DOI: 10.1385/Jcd:6:4:323 |
0.316 |
|
| 2003 |
Muindi JR, Wilson JW, Peng Y, Capozolli MJ, Johnson CS, Trump DL. A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients. Journal of Clinical Pharmacology. 43: 894-900. PMID 12953346 DOI: 10.1177/0091270003255925 |
0.505 |
|
| 2003 |
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, White RWd, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The New England Journal of Medicine. 349: 859-866. PMID 12944571 DOI: 10.1056/Nejmoa022148 |
0.341 |
|
| 2003 |
Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis. 24: 1665-70. PMID 12896904 DOI: 10.1093/Carcin/Bgg123 |
0.568 |
|
| 2003 |
Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): An eastern cooperative oncology group study Medical Oncology. 20: 137-145. PMID 12835516 DOI: 10.1385/Mo:20:2:137 |
0.377 |
|
| 2003 |
Xiao D, Srivastava SK, Lew KL, Zeng Y, Hershberger P, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis. 24: 891-7. PMID 12771033 DOI: 10.1093/Carcin/Bgg023 |
0.574 |
|
| 2003 |
Trump D, Lau YK. Chemotherapy of prostate cancer: present and future. Current Urology Reports. 4: 229-32. PMID 12756087 DOI: 10.1007/S11934-003-0074-3 |
0.391 |
|
| 2003 |
Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer PJ. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer. 97: 1869-75. PMID 12673712 DOI: 10.1002/Cncr.11271 |
0.331 |
|
| 2003 |
Trump DL. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M, Department of Medicine, University of Chicago, Chicago, IL Urologic Oncology-Seminars and Original Investigations. 21: 413. DOI: 10.1016/S1078-1439(03)00118-2 |
0.338 |
|
| 2003 |
Trump DL. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX Urologic Oncology-Seminars and Original Investigations. 21: 412. DOI: 10.1016/S1078-1439(03)00116-9 |
0.403 |
|
| 2003 |
Trump DL. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA Urologic Oncology-Seminars and Original Investigations. 21: 411-412. DOI: 10.1016/S1078-1439(03)00115-7 |
0.389 |
|
| 2003 |
Trump DL. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ, Mayo Clinic and Mayo Foundation, Rochester, MN Urologic Oncology-Seminars and Original Investigations. 21: 409-410. DOI: 10.1016/S1078-1439(03)00114-5 |
0.408 |
|
| 2003 |
Trump DL. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l’Université, de Montreal, Hôpital Notre-Dame, Montréal, Québec, Canada Urologic Oncology-Seminars and Original Investigations. 21: 408. DOI: 10.1016/S1078-1439(03)00112-1 |
0.337 |
|
| 2003 |
Trump DL. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD Urologic Oncology-Seminars and Original Investigations. 21: 410-411. DOI: 10.1016/S1078-1439(03)00111-X |
0.387 |
|
| 2003 |
Trump DL. Commentary on the next two abstracts follows the second abstract. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD Urologic Oncology-Seminars and Original Investigations. 21: 410. DOI: 10.1016/S1078-1439(03)00110-8 |
0.346 |
|
| 2002 |
Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clinical Pharmacology and Therapeutics. 72: 648-59. PMID 12496746 DOI: 10.1067/Mcp.2002.129305 |
0.526 |
|
| 2002 |
Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL, Johnson CS. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Molecular Cancer Therapeutics. 1: 821-9. PMID 12492115 |
0.545 |
|
| 2002 |
Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Reviews. 21: 147-58. PMID 12465754 DOI: 10.1023/A:1020836226594 |
0.646 |
|
| 2002 |
Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemotherapy and Pharmacology. 50: 433-44. PMID 12451469 DOI: 10.1007/S00280-002-0517-4 |
0.485 |
|
| 2002 |
Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology. 60: 553-61. PMID 12385906 DOI: 10.1016/S0090-4295(02)01741-7 |
0.557 |
|
| 2002 |
Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL. Vitamin D receptor: a potential target for intervention. Urology. 60: 123-30; discussion 1. PMID 12231068 DOI: 10.1016/S0090-4295(02)01591-1 |
0.603 |
|
| 2002 |
Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. Cancer Chemotherapy and Pharmacology. 50: 179-85. PMID 12203099 DOI: 10.1007/S00280-002-0484-9 |
0.478 |
|
| 2002 |
Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. The Journal of Urology. 168: 756-61. PMID 12131364 DOI: 10.1016/S0022-5347(05)64740-4 |
0.577 |
|
| 2002 |
Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology. 143: 2508-14. PMID 12072382 DOI: 10.1210/Endo.143.7.8887 |
0.611 |
|
| 2001 |
Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V. Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism: Clinical and Experimental. 50: 1242-7. PMID 11586501 DOI: 10.1053/Meta.2001.26714 |
0.323 |
|
| 2001 |
McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. The Journal of Biological Chemistry. 276: 26365-73. PMID 11331275 DOI: 10.1074/Jbc.M010101200 |
0.589 |
|
| 2001 |
Obasaju C, Manola J, Hudes GR, Khandekar JD, Citrin DL, Carbone P, Trump DL. Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. American Journal of Clinical Oncology. 24: 150-154. PMID 11319290 DOI: 10.1097/00000421-200104000-00011 |
0.391 |
|
| 2001 |
Trump DL, Waldstreicher JA, Kolvenbag G, Wissel PS, Neubauer BL. Androgen antagonists: Potential role in prostate cancer prevention Urology. 57: 64-67. PMID 11295597 DOI: 10.1016/S0090-4295(00)00943-2 |
0.408 |
|
| 2001 |
Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Investigational New Drugs. 19: 89-92. PMID 11291838 DOI: 10.1023/A:1006458232384 |
0.305 |
|
| 2001 |
Konety BR, Lavelle JP, Pirtskalaishvili G, Dhir R, Meyers SA, Nguyen TS, Hershberger P, Shurin MR, Johnson CS, Trump DL, Zeidel ML, Getzenberg RH. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. The Journal of Urology. 165: 253-8. PMID 11125420 DOI: 10.1097/00005392-200101000-00074 |
0.633 |
|
| 2000 |
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, ... ... Trump DL, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3461-7. PMID 10550143 DOI: 10.1200/Jco.1999.17.11.3461 |
0.374 |
|
| 1999 |
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. The New England Journal of Medicine. 341: 1781-8. PMID 10588962 DOI: 10.1056/Nejm199912093412401 |
0.368 |
|
| 1999 |
Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 2506-13. PMID 10561316 DOI: 10.1200/Jco.1999.17.8.2506 |
0.406 |
|
| 1999 |
Woolley PV, Freiha FS, Smith DC, Carlson L, Hofacker J, Quinn N, Grove W, Trump DL. A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 44: 511-7. PMID 10550573 DOI: 10.1007/S002800051126 |
0.372 |
|
| 1999 |
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone (H) With Or Without Mitoxantrone (M) In Men With Hormone Refractory Prostate Cancer (Hrpc). The Results Of Calgb 9182 The Journal of Urology. 176. DOI: 10.1097/00005392-199904010-00708 |
0.356 |
|
| 1999 |
Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate Hormonal Therapy Vs. Observation For Node Positive Prostate Cancer Following Radical Prostatectomy And Pelvic Lymphadenectomy: A Randomized Phase Iii Eastern Cooperative Oncology Group/Inter Group Trial The Journal of Urology. 175. DOI: 10.1097/00005392-199904010-00701 |
0.342 |
|
| 1998 |
Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. Journal of the National Cancer Institute. 90: 134-41. PMID 9450573 DOI: 10.1093/Jnci/90.2.134 |
0.592 |
|
| 1997 |
Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50: 999-1006. PMID 9426741 DOI: 10.1016/S0090-4295(97)00408-1 |
0.58 |
|
| 1997 |
Yu WD, Chang MJ, Trump DL, Johnson CS. Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity. Cancer Immunology, Immunotherapy : Cii. 44: 316-22. PMID 9298933 DOI: 10.1007/S002620050388 |
0.478 |
|
| 1997 |
Osborn JL, Smith DC, Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer American Journal of Clinical Oncology: Cancer Clinical Trials. 20: 308-310. PMID 9167760 DOI: 10.1097/00000421-199706000-00021 |
0.4 |
|
| 1997 |
Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology. 39: 349-56. PMID 9025776 DOI: 10.1007/S002800050582 |
0.337 |
|
| 1996 |
Witte RS, Hsieh P, Elson P, Oken MM, Trump DL. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Investigational New Drugs. 14: 409-13. PMID 9157078 DOI: 10.1007/Bf00180819 |
0.305 |
|
| 1996 |
Chang AY, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Journal of Clinical Oncology. 14: 2250-2257. PMID 8708714 DOI: 10.1200/Jco.1996.14.8.2250 |
0.418 |
|
| 1995 |
Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urologic Oncology. 1: 195-8. PMID 21224117 DOI: 10.1016/1078-1439(95)00061-5 |
0.492 |
|
| 1995 |
Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer Journal of Neuro-Oncology. 23: 135-147. PMID 7543940 DOI: 10.1007/Bf01053418 |
0.338 |
|
| 1994 |
Chang AY, Tu ZN, Bryan GT, Kirkwood JM, Oken MM, Trump DL. Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885 Investigational New Drugs. 12: 151-153. PMID 7860234 DOI: 10.1007/Bf00874447 |
0.308 |
|
| 1994 |
Trump DL, Hathorn JA, Grochow LB, Spriggs D, Eble ML, Hohneker JA. Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer. Investigational New Drugs. 12: 273-276. PMID 7775126 DOI: 10.1007/Bf00873040 |
0.37 |
|
| 1993 |
Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan TT, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 11: 561-569. PMID 8445432 DOI: 10.1200/Jco.1993.11.3.561 |
0.332 |
|
| 1993 |
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 2167-72. PMID 8229130 DOI: 10.1200/Jco.1993.11.11.2167 |
0.415 |
|
| 1988 |
Heney NM, Koontz WW, Barton B, Soloway M, Trump DL, Hazra T, Weinstein RS. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. The Journal of Urology. 140: 1390-3. PMID 3143016 DOI: 10.1016/S0022-5347(17)42052-0 |
0.312 |
|
| 1986 |
Glover D, Trump D, Kvols L, Elson P, Vogl S. Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. International Journal of Radiation Oncology Biology Physics. 12: 1405-1408. PMID 3759565 DOI: 10.1016/0360-3016(86)90182-3 |
0.352 |
|
| 1984 |
Haupt HM, Mann RB, Trump DL, Abeloff MD. Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms. Cancer. 54: 709-714. PMID 6204734 DOI: 10.1002/1097-0142(1984)54:4<709::Aid-Cncr2820540419>3.0.Co;2-6 |
0.322 |
|
| 1981 |
Trump DL, Ettinger DS, Feldman MJ, Dragon LH. 'Sarcoidosis' and sarcoid-like lesions. Their occurrence after cytotoxic and radiation therapy of testis cancer. Archives of Internal Medicine. 141: 37-8. PMID 7447582 DOI: 10.1001/Archinte.1981.00340010033010 |
0.319 |
|
| 1981 |
Trump DL, Ettinger DS, Abeloff MD. Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer Medical and Pediatric Oncology. 9: 1-3. PMID 7007853 DOI: 10.1002/Mpo.2950090102 |
0.325 |
|
| 1981 |
Abeloff MD, Trump DL, Baylin SB. Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung-assessment of clinical implications in patients on combination chemotherapy. Cancer. 48: 1082-7. PMID 6268276 DOI: 10.1002/1097-0142(19810901)48:5<1082::Aid-Cncr2820480505>3.0.Co;2-J |
0.303 |
|
| Show low-probability matches. |
